Evidence map›Paper›PMID 10438847›Full record

ArticleJournal of virology1999

Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein.

A H Choi, M Basu, M M McNeal, J D Clements, R L Ward

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 99 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Development of a Bacillus subtilis-based rotavirus vaccine.Clinical and vaccine immunology : CVI · 2010
    Article
  16. Article
  17. Plant production of veterinary vaccines and therapeutics.Current topics in microbiology and immunology · 2009
    Review
  18. Article
  19. Article
  20. Why does the world need another rotavirus vaccine?Therapeutics and clinical risk management · 2008
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

A H ChoiDivision of Infectious Diseases, Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA. achoi@chmcc.org
M Basu
M M McNeal
J D Clements
R L Ward
Cincinnati Children's Hospital Medical Center · USTulane University · US

Funding

EVALUATING NON-AIDS INFECTIOUS DISEASE CONTROL MEASURES-266945252N01AI045252 · NIAID · CHILDREN'S HOSPITAL MED CTR (CINCINNATI) · 1994 to 2003
$1.6M
NIAID NIH HHS N01 AI 45252
6 · The paper itself

Abstract

This study was to determine whether individual rotavirus capsid proteins could stimulate protection against rotavirus shedding in an adult mouse model. BALB/c mice were intranasally or intramuscularly administered purified Escherichia coli-expressed murine rotavirus strain EDIM VP4, VP6, or truncated VP7 (TrVP7) protein fused to the 42.7-kDa maltose-binding protein (MBP). One month after the last immunization, mice were challenged with EDIM and shedding of rotavirus antigen was measured. When three 9-microg doses of one of the three rotavirus proteins fused to MBP were administered intramuscularly with the saponin adjuvant QS-21, serum rotavirus immunoglobulin G (IgG) was induced by each protein. Following EDIM challenge, shedding was significantly (P = 0.02) reduced (i.e., 38%) in MBP::VP6-immunized mice only. Three 9-micrograms doses of chimeric MBP::VP6 or MBP::TrVP7 administered intranasally with attenuated E. coli heat-labile toxin LT(R192G) also induced serum rotavirus IgG, but MBP::VP4 immunization stimulated no detectable rotavirus antibody. No protection against EDIM shedding was observed in the MBP::TrVP7-immunized mice. However, shedding was reduced 93 to 100% following MBP::VP6 inoculation and 56% following MBP::VP4 immunization relative to that of controls (P = <0.001). Substitution of cholera toxin for LT(R192G) as the adjuvant, reduction of the number of doses to 1, and challenge of the mice 3 months after the last immunization did not reduce the level of protection stimulated by intranasal administration of MBP::VP6. When MBP::VP6 was administered intranasally to B-cell-deficient microMt mice that made no rotavirus antibody, shedding was still reduced to <1% of that of controls. These results show that mice can be protected against rotavirus shedding by intranasal administration of individual rotavirus proteins and that this protection can occur independently of rotavirus antibody.

Indexed as

Antigens, ViralATP-Binding Cassette TransportersCapsid ProteinsEscherichia coli ProteinsMonosaccharide Transport ProteinsAdministration, IntranasalAnimalsAntibodies, ViralBacterial ToxinsB-LymphocytesCapsidCarrier ProteinsCholera ToxinChromatography, AffinityEnterotoxinsEscherichia coliAntibodies, ViralAntigens, ViralATP-Binding Cassette TransportersBacterial ToxinsCapsid ProteinsCarrier ProteinsCholera ToxinEnterotoxinsEscherichia coli Proteinsheat-labile enterotoxin, E coliImmunoglobulin GMaltose-Binding Proteinsmaltose transport system, E coliMonosaccharide Transport ProteinsRecombinant Fusion ProteinsVP4 protein, RotavirusVP6 protein, Rotavirus

Identifiers

PMID10438847
PMCPMC104284
OpenAlexW2150320221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.